Sourcing Products and Technologies
Our approach has been to create or license-in appropriate patents, technologies and know-how where necessary and further develop the product on a proprietary basis. Where appropriate, we have subsequently acquired relevant intellectual property and, as a result, we have a broad proprietary intellectual property portfolio of granted patents and patent applications in various jurisdictions around the world. We currently own all patents and intellectual property in relation to cetilistat, COLAL-PRED® and ATL-104.
Our existing portfolio of three late stage drug candidates has derived from a variety of sources.
COLAL-PRED®
COLAL-PRED® is a proprietary product developed by Alizyme and has arisen from combining COLAL®, a drug delivery technology, with prednisolone, a generic steroid. COLAL® was originally accessed and then licensed through a series of agreements with BTG International Ltd (now BTG plc), commencing in 1996. In March 2005, we acquired the patents that relate to the COLAL® technology from BTG plc.
ATL-104
ATL-104 resulted from a research discovery made at Rowett Research Institute in Scotland, with whom we had a development programme. We subsequently acquired the rights to ATL-104 under a series of agreements in 1996 and 1997 and have applied it to the treatment of mucositis.
COLAL®
The COLAL® drug delivery system was initially developed in a collaboration between the London University School of Pharmacy, the MRC Dunn Clinical Nutrition Centre in Cambridge, UK and the Institute of Food Research in Norwich, UK. COLAL® was originally accessed and then licensed through a series of agreements with BTG International Ltd (now BTG plc), commencing in 1996. In March 2005, we acquired the patents that relate to the COLAL® technology from BTG plc. We have taken COLAL® from the research stage and developed it into a drug delivery system suitable for pharmaceutical application.
(Note: COLAL® and COLAL-PRED® are registered trademarks of Alizyme Therapeutics Limited)